@avidresearch @STL_Biotech $NKTR's problem, like $FPRX, and others, is they did all their combination studies to date with $BMY's Opdivio instead of $MRK's Keytruda, a much better drug.  And, the data hasn't been good enough.  There's a lesson there for other small-and-mid-cap biotechs.